Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292831 | 0.87 | CYP3A4 (0.32) | RECQLUSP2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5717394 | 0.87 | CYP3A4 (0.32) | RECQLUSP2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5717155 | 0.86 | SMN1; SMN2 (0.34) | RECQLUSP2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5717453 | 0.83 | SMN1; SMN2 (0.36) | RECQLUSP2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5839777 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL5840487 | 0.80 | POLB (0.32) | RECQLSMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL5840483 | 0.80 | POLB (0.32) | RECQLSMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL5717237 | 0.80 | NR1H2 (0.36) | RECQLUSP2SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5717186 | 0.79 | ADAMTS4 (0.33) | RECQLUSP2SMN1; SMN2 | |
| SCHEMBL5717379 | 0.79 | CYP4F2 (0.34) | RECQLUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1689743-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-09-22 | — | — | US | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | RECQL 2308/4885USP2 270/4885SMN1; SMN2 1895/4885 |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | RECQL 2308/4885USP2 270/4885SMN1; SMN2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.